Studying Immune and Viral Changes During Early HIV Infection Using Combination Anti-Retroviral Therapy A Long-Term Observational Study

What This Trial Is About

Researchers are studying how the immune system and HIV virus behave in people who start combination anti-retroviral therapy cART very early during acute HIV infection. The goal is to understand changes in the HIV viral reservoir that causes the virus to return when treatment stops. This observational study focuses on patients recently infected with HIV and uses detailed sampling over time to track these changes. Participants will begin early combination anti-retroviral treatment to suppress the HIV virus during the acute seroconversion phase. The study involves extensive sampling including colon biopsies, lymph node removal, lumbar puncture, leukapheresis, and repeated blood draws. This sampling happens at different times over a two-year follow-up period to analyze immune, viral, and genetic data. During the study, participants will undergo various procedures and visits for sample collection and testing. Researchers will evaluate how immune and viral factors evolve in the HIV reservoir over ten years. They will also study changes in the microbiome. The study requires participants to attend scheduled visits and provide samples that may be stored indefinitely for research. Overall participation and monitoring last up to ten years.

Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection